Maigrir_OT
RecruitingPhase NAEffect of Agonist GLP1 on Adipose Tissue in Patients Undergoing Bariatric Surgery
Lead sponsor
Asset
GLP-1 / incretin class catch-all
Listed sites
1
Recruiting sites
1
Estimated enrollment
40
Study population
Bariatric Surgery, Obesity / overweight
Eligibility highlights
•BMI ≥35
Primary endpoint
•Oxytocin
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who this study enrolls
Who can enroll
Inclusion criteria
Exclusion criteria
Endpoints (2)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Other (unclassified)
2 endpointsRate of oxytocin
Time frame:one time (before surgery)
change from baseline, improvement
Fibrosis rate
Time frame:At surgery
descriptive
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.